ÂÜÀòÂÒÂ×

Oren Gilad, Ph.D., has served as their Chief Executive Officer since July 2022 and as President and a member of the board of directors since May 2022. He previously served as President and CEO of Atrin Pharmaceuticals Inc. at the time of its acquisition by Aprea. He brings extensive experience across multiple phases of drug development. Prior to founding Atrin in 2011, Dr. Gilad authored several high impact scientific publications over the course of a 13 year academic career, including demonstration of the importance of the ATR pathway in cancer development and treatment. Dr. Gilad holds a Ph.D from University of California at Davis and a B.Sc from the Hebrew University.